ArticleBMC cancer2026

A single-cell derived immune risk score predicts recurrence in NSCLC following neoadjuvant chemo-immunotherapy.

Jun Ge et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.